Journal of Gastroenterology

, Volume 49, Issue 4, pp 674–682

Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn’s disease under scheduled maintenance treatment

  • Hirotsugu Imaeda
  • Shigeki Bamba
  • Kenichiro Takahashi
  • Takehide Fujimoto
  • Hiromitsu Ban
  • Tomoyuki Tsujikawa
  • Masaya Sasaki
  • Yoshihide Fujiyama
  • Akira Andoh
Original Article—Alimentary Tract

Abstract

Background and aims

Few data are available to support the clinical relevance of infliximab (IFX) trough levels for prediction of endoscopic disease activity in Crohn’s disease (CD). This study evaluated the endoscopic disease activities in relation to clinical outcome using several laboratory markers including serum IFX trough levels in patients with CD undergoing scheduled IFX maintenance treatment.

Materials and methods

A total of 78 sessions of endoscopy were performed on 45 patients with CD. Endoscopic activity was assessed using the modified Rutgeerts scoring system. IFX trough levels and anti-IFX antibodies (ATIs) were determined by immunoassays.

Results

Endoscopic activity negatively correlated with serum IFX trough levels (Spearman’s rank correlation coefficient (ρ) = −0.54, P < 0.0001) and serum albumin levels (ρ = −0.46, P < 0.0001), and positively correlated with CRP (C-reactive protein) levels (ρ = 0.55, P < 0.0001), ESR (erythrocyte sedimentation rate) (ρ = 0.47, P < 0.0001) and fecal calprotectin levels. IFX trough levels and serum albumin levels were significantly elevated in the mucosal healing (MH) group, but ATIs, CRP, ESR and fecal calprotectin levels were significantly elevated in the nonmucosal healing group. Receiver operation curve revealed that the optimal cutoff value of IFX trough levels for identifying normal laboratory markers was 0.6 μg/ml for CRP, 1.0 μg/ml for serum albumin and 1.1 μg/ml for fecal calprotectin. Identification of mucosal healing needed a higher cutoff value of 4.0 μg/ml. Thiopurine treatment did not affect IFX trough and ATI levels.

Conclusion

Mucosal healing requires higher IFX trough levels, compared to those to achieve normalization of routine clinical markers.

Keywords

Anti-infliximab antibodies Mucosal healing Receiver operation curve 

References

  1. 1.
    Allez M, Vermeire S, Mozziconacci N, et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn’s disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther. 2010;31:92–101.PubMedCrossRefGoogle Scholar
  2. 2.
    Danese S, Colombel JF, Reinisch W, et al. Review article: infliximab for Crohn’s disease treatment—shifting therapeutic strategies after 10 years of clinical experience. Aliment Pharmacol Ther. 2011;33:857–69.PubMedCrossRefGoogle Scholar
  3. 3.
    Mayer L. Evolving paradigms in the pathogenesis of IBD. J Gastroenterol. 2010;45:9–16.PubMedCrossRefGoogle Scholar
  4. 4.
    Hanauer SB, Kornbluth AA, Messick J, et al. Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. Inflamm Bowel Dis. 2010;16(Suppl 1):S1–11.PubMedCrossRefGoogle Scholar
  5. 5.
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65.PubMedCrossRefGoogle Scholar
  7. 7.
    Ueno F, Matsui T, Matsumoto T, et al. Evidence-based clinical practice guidelines for Crohn’s disease, integrated with formal consensus of experts in Japan. J Gastroenterol. 2013;48:31–72.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Andoh A, Kuzuoka H, Tsujikawa T, et al. Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn’s disease. J Gastroenterol. 2012;47:1298–307.PubMedCrossRefGoogle Scholar
  9. 9.
    D’Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011;106:199–212 (quiz 213).Google Scholar
  10. 10.
    Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort. Gut. 2009;58:492–500.PubMedCrossRefGoogle Scholar
  11. 11.
    Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350:876–85.PubMedCrossRefGoogle Scholar
  12. 12.
    Van Assche G, Magdelaine-Beuzelin C, D’Haens G, et al. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008;134:1861–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol. 2009;104:760–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011;106:685–98.PubMedCrossRefGoogle Scholar
  15. 15.
    Bortlik M, Duricova D, Malickova K, et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn’s disease. J Crohns Colitis. 2012. doi:10.1016/j.crohns.2012.10.019.
  16. 16.
    Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin Gastroenterol Hepatol. 2006;4:1248–54.PubMedCrossRefGoogle Scholar
  17. 17.
    Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn’s disease: a critical systematic review. Inflamm Bowel Dis. 2009;15:1264–75.PubMedCrossRefGoogle Scholar
  18. 18.
    Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol. 2004;2:542–53.PubMedCrossRefGoogle Scholar
  19. 19.
    Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut. 2007;56:1226–31.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Imaeda H, Andoh A, Fujiyama Y. Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease. J Gastroenterol. 2012;47:136–43.PubMedCrossRefGoogle Scholar
  21. 21.
    Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol. 2013;108:40–7.Google Scholar
  22. 22.
    Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–95.PubMedCrossRefGoogle Scholar
  23. 23.
    Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology. 2010;138:463–8 (quiz e410–461).Google Scholar
  24. 24.
    Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease. Inflamm Bowel Dis. 2009;15:1295–301.PubMedCrossRefGoogle Scholar
  25. 25.
    Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn’s disease. Gastroenterology. 1990;99:956–63.PubMedGoogle Scholar
  26. 26.
    Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn’s disease: a prospective multicentre study. Groupe d’Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut. 1989;30:983–9.Google Scholar
  27. 27.
    Daperno M, D’Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc. 2004;60:505–12.PubMedCrossRefGoogle Scholar
  28. 28.
    af Bjorkesten CG, Nieminen U, Turunen U, et al. Endoscopic monitoring of infliximab therapy in Crohn’s disease. Inflamm Bowel Dis. 2011;17:947–53.Google Scholar
  29. 29.
    Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 2012;61:1619–35.PubMedCrossRefGoogle Scholar
  30. 30.
    Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141:1194–201.PubMedCrossRefGoogle Scholar
  31. 31.
    Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest Endosc. 2006;63:433–42 (quiz 464).Google Scholar
  32. 32.
    Steenholdt C, Bendtzen K, Brynskov J, et al. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn’s disease. Scand J Gastroenterol. 2011;46:310–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Hibi T, Sakuraba A, Watanabe M, et al. Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn’s disease. Inflamm Bowel Dis. 2012;18:1480–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Fasanmade AA, Adedokun OJ, Olson A, et al. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther. 2010;48:297–308.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2013

Authors and Affiliations

  • Hirotsugu Imaeda
    • 2
  • Shigeki Bamba
    • 2
  • Kenichiro Takahashi
    • 1
  • Takehide Fujimoto
    • 1
  • Hiromitsu Ban
    • 2
  • Tomoyuki Tsujikawa
    • 2
  • Masaya Sasaki
    • 2
  • Yoshihide Fujiyama
    • 2
  • Akira Andoh
    • 1
  1. 1.Division of Mucosal Immunology, Graduate SchoolShiga University of Medical ScienceOtsuJapan
  2. 2.Department of MedicineShiga University of Medical ScienceOtsuJapan

Personalised recommendations